Intest Res.  2017 Oct;15(4):487-494. 10.5217/ir.2017.15.4.487.

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

Affiliations
  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
  • 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • 3Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan.
  • 4Department of Gastroenterology, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 5Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • 6Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
  • 7Department of Internal Medicine, National Cheng-Kung University Hospital, National Cheng-Kung University Medical College, Tainan, Taiwan.
  • 8Department of Gastroenterology, Tri-Service General Hospital, Taipei, Taiwan.
  • 9Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. shuchenwei@ntu.edu.tw

Abstract

BACKGROUND/AIMS
In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically focusing on the relapse rate and remission duration; also the response rate to second use when applicable.
METHODS
This was a multicenter, retrospective, observational study and we enrolled CD patients who had been treated with adalimumab (ADA) according to the insurance guidelines from 2009 to 2015.
RESULTS
A total of 54 CD patients, with follow-up of more than 6 months after the withdrawal of ADA, were enrolled. The average period of treatment with ADA was 16.7±9.7 months. After discontinuing ADA, 59.3% patients suffered a clinical relapse. In the univariate analysis, the reason for withdrawal was a risk factor for relapse (P=0.042). In the multivariate analysis, current smoker became an important risk factor for relapse (OR, 3.9; 95% CI, 1.2−14.8; P=0.044) and male sex was another risk factor (OR, 2.9; 95% CI, 1.1−8.6; P=0.049). For those 48 patients who received a second round of biologics, the clinical response was seen in 60.4%, and 1 anaphylaxis occurred.
CONCLUSIONS
Fifty-nine percent of patients experienced a relapse after discontinuing the limited period of ADA treatment, and most of them occurred within 1 year following cessation. Male sex and current smoker were risk factors for relapse. Though 60.4% of the relapse patients responded to ADA again.

Keyword

Crohn disease; Adalimumab; Withdraw

MeSH Terms

Adalimumab*
Anaphylaxis
Biological Products
Budgets
Crohn Disease*
Follow-Up Studies
Humans
Inflammatory Bowel Diseases*
Insurance
Male
Multivariate Analysis
National Health Programs
Observational Study
Recurrence
Retrospective Studies
Risk Factors
Taiwan*
Adalimumab
Biological Products

Figure

  • Fig. 1 Flow chart of the patients in the study.

  • Fig. 2 Kaplan-Meier time-to-relapse curve of the 54 included patients. There were 32 patients with confirmed relapse. The median time to relapse was 14 months.

  • Fig. 3 Medication usage before, during and after biologic agent. ADA, adalimumab.


Cited by  2 articles

Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
Korean J Gastroenterol. 2020;75(1):29-38.    doi: 10.4166/kjg.2020.75.1.29.

Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
Intest Res. 2019;17(1):54-62.    doi: 10.5217/ir.2018.00096.


Reference

1. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011; 106:199–212. PMID: 21045814.
2. Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015; 15:178. PMID: 26678147.
Article
3. Pittet V, Froehlich F, Maillard MH, et al. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013; 7:820–826. PMID: 23664620.
Article
4. The application form of adalimumab for Crohn's disease in national health insurance. Accessed July 31, 2017. http://www.realsun.com.tw/new_web/pdf/100n_123.pdf.
5. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126:1518–1532. PMID: 15168364.
Article
6. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128:862–869. PMID: 15825070.
Article
7. Nakase H, Keum B, Ye BD, Park SJ, Koo HS, Eun CS. Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res. 2016; 14:231–239. PMID: 27433145.
Article
8. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016; 111:632–647. PMID: 27002797.
Article
9. Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015; 149:1716–1730. PMID: 26381892.
Article
10. Rismo R, Olsen T, Cui G, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Scand J Gastroenterol. 2013; 48:311–319. PMID: 23302000.
Article
11. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012; 142:63–70.e5. PMID: 21945953.
Article
12. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008; 30:523–529. PMID: 18641542.
Article
13. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol. 2012; 107:1409–1422. PMID: 22890223.
Article
14. Duffy LC, Zielezny MA, Marshall JR, et al. Cigarette smoking and risk of clinical relapse in patients with Crohn's disease. Am J Prev Med. 1990; 6:161–166. PMID: 2397140.
Article
15. Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease. Br J Surg. 2000; 87:398–404. PMID: 10759731.
Article
16. Nunes T, Etchevers MJ, García-Sánchez V, et al. Impact of smoking cessation on the clinical course of Crohn's disease under current therapeutic algorithms: a multicenter prospective study. Am J Gastroenterol. 2016; 111:411–419. PMID: 26856753.
Article
17. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of charm. J Crohns Colitis. 2007; 1(Suppl 1):49.
Article
18. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012; 47:518–527. PMID: 22375898.
Article
19. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 64:704–707. PMID: 15485995.
Article
20. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19:2111–2117. PMID: 23883959.
Article
21. Lasson A, Simrén M, Stotzer PO, Isaksson S, Ohman L, Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013; 19:576–581. PMID: 23377170.
Article
22. Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011; 34:462–469. PMID: 21671970.
Article
23. Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016; 43:910–923. PMID: 26892328.
Article
24. Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2016; 50:147–151. PMID: 25811118.
Article
25. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99:956–963. PMID: 2394349.
Article
26. Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 2014; 24:212–225.
27. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011; 106:547–548. PMID: 21624763.
Article
28. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009; 124:1259–1266. PMID: 19910036.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr